Showing papers in "Blood in 2013"

TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.

TL;DR: Analysis of oncogenic mutations in large, well-characterized cohorts of patients illustrates the interconnections between the cancer genome and disease biology, with considerable potential for clinical application.

TL;DR: Clinical testing of engineered T cells expressing an affinity-enhanced TCR against HLA-A*01-restricted MAGE-A3 demonstrated that TCR-engineered T cells can have serious and not readily predictable off-target and organ-specific toxicities and highlight the need for improved methods to define the specificity of engineeredTCRs.

TL;DR: This review describes the literature on incidence of and risk factors for cancer-associated venous thrombosis to provide a basis for identification of high-risk patients and for further development and refinement of prediction models.

TL;DR: The evidence that neutrophil extracellular traps (NETs) play a critical role in innate immunity is examined and how infections are related to the development of autoimmune and vasculitic diseases through unintended but detrimental bystander damage resulting from NET release is examined.

TL;DR: Careful immunosurveillance conducted as part of ongoing clinical studies will provide the basis for understanding the intricacies of the immune response in AAV-mediated gene transfer, facilitating safe and effective therapies for genetic diseases.

TL;DR: Ibrutinib is established as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility and ITK as an irreversible T-cell target of ibrut inib.

TL;DR: The results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse, and show persistence of the original CML clone in all patients with stable U MRD, even several years after imatinIB withdrawal.

TL;DR: The characterization of EPZ-5676 is described, a potent and selective aminonucleoside inhibitor of DOT1L histone methyltransferase activity that demonstrates 37 000-fold selectivity over all other methyltransferases tested.

TL;DR: A positive role for mast cells in tissue inflammation is demonstrated and how this comes about with contribution from a second tissue cell, the macrophage is defined.

TL;DR: The results for adult umbilical cord blood transplantation have improved, with greater emphasis on cord blood units of sufficient cell dose and human leukocyte antigen match and with the use of double umbilicals Cord blood units and improved supportive care techniques.

TL;DR: This perspective reviews the principal mechanisms of Hb and hemin toxicity in different disease states, updates how the natural scavengers efficiently control these toxic moieties, and explores critical issues in the development of human plasma-derived Hp and hemopexin as therapeutics for patients with excessive intravascular hemolysis.

TL;DR: It is concluded that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL.

TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

TL;DR: This is the first report of a specific antidote for a next-generation anticoagulant that may become a valuable tool in patients who require emergency procedures.

TL;DR: Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program and Guidelines were developed on the basis of a list of patient- and therapy-oriented questions.

TL;DR: In this study, the addition of GO to induction or postconsolidation therapy failed to show improvement in CR rate, disease-free survival, or overall survival.

TL;DR: Results show for the first time that donor-derived allogeneic anti-CD19-CAR T cells can cause regression of B-cell malignancies resistant to standard DLIs without causing GVHD.

TL;DR: Patients treated with T cell-activating therapies, including blinatumomab, should be monitored for HLH, and cytokine-directed therapy may be considered in cases of life-threatening CRS.

TL;DR: It is concluded that second-generation m971 mAb-derived anti-CD22 CARs are promising novel therapeutics that should be tested in BCP-ALL.

TL;DR: A combined immunohistochemistry or FISH/immunohistochemical score predicts outcome in DLBCL patients independent of the IPI and identifies a subset of 15% of patients with dismal prognosis in the high-risk IPI group following treatment with R-CHOP.

TL;DR: These results demonstrated that the mutation/deletion status of a set of genes could be used as variables independent of clinical parameters to build a clinically relevant prognostic score.

TL;DR: The use of banked third-party VSTs is a feasible and safe approach to rapidly treat severe or intractable viral infections after stem cell transplantation.

TL;DR: Treatment with vemurafenib, a newly approved BRAF inhibitor, should be considered for patients with severe and refractory BRAFV600E histiocytoses, particularly when the disease is life-threatening.

TL;DR: It is shown that it is possible to differentiate in vitro, expand, and gene modify in clinically compliant conditions CD8(+) T(SCM) lymphocytes starting from naive precursors, suggesting self-renewal capacity in a clinically relevant setting.

TL;DR: The results provide new insight into the diversity of KIR repertoire and its adaptation to virus infection, suggesting a role for both activating and inhibitory KIRs in immunity to CMV infection.

TL;DR: CD19.CAR-VSTs display antitumor activity and, because their number may be increased in the presence of viral stimuli, earlier treatment post-HSCT (when lymphodepletion is greater and the incidence of viral infection is higher) or planned vaccination with viral antigens may enhance disease control.

TL;DR: Macrophage-derived microvesicles are characterized and their role in the differentiation of naive monocytes is explored and the miRNA content is identified, finding that RNA molecules contained in the macrophages were transported to target cells, including mono cytes, endothelial cells, epithelial Cells, and fibroblasts.

TL;DR: It is demonstrated that miR-214, an miRNA that controls endothelial cell function and angiogenesis, plays a dominant role in exosome-mediated signaling between endothelial cells.

TL;DR: This work analyzes and compares the transcriptome and proteome of human and murine macrophages under resting conditions (M0) and after IL-4 activation (M2) and provides a resource for tools enabling macrophage detection in human tissues by identifying a set of 87 Macrophage-related genes.